CoreCap Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

CoreCap Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$2.48K	Buy	+2,801	New	+$3.72K	﹤0.01%	1895
2022 Q3	–	Sell	-2,801	Closed	-$6K	–	2311
2022 Q2	$6K	Buy	+2,801	New	+$4.84K	﹤0.01%	1652
2022 Q1	–	Sell	-2,801	Closed	-$13K	–	2305
2021 Q4	$13K	Buy	+2,801	New	+$17.4K	﹤0.01%	1477

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BRF

B. Riley Financial Los Angeles, California $434M AUM 751.56% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

CoreCap Advisors's SRNE Position: Q4 2022 in Review

CoreCap Advisors opened a new position in Sorrento Therapeutics, Inc. (SRNE) in Q4 2022: 2,801 shares worth $2.48K. The stake represents ﹤0.01% of the portfolio and ranks #1895 among its holdings. This is a return to the name: CoreCap Advisors previously reported a position in SRNE as recently as Q2 2022.

CoreCap Advisors first reported a position in SRNE in Q4 2021 and has held it in 3 quarters since. The position peaked at $13K in Q4 2021. 221 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

CoreCap Advisors held 2,801 shares of Sorrento Therapeutics, Inc. worth $2.48K as of Q4 2022.
Sorrento Therapeutics, Inc. was a new CoreCap Advisors position in Q4 2022.
Sorrento Therapeutics, Inc. made up ﹤0.01% of CoreCap Advisors's portfolio in Q4 2022, its #1895 holding.
CoreCap Advisors first reported a position in Sorrento Therapeutics, Inc. in Q4 2021 and has held it in 3 quarters since.
CoreCap Advisors's Sorrento Therapeutics, Inc. position peaked at $13K in Q4 2021.
221 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on CoreCap Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.